Introduction - This article presents the prevalence of chronic viral hepatitis B (HBV) and C (HCV) among patients diagnosed with hepatocellular carcinoma (HCC) in France’s overseas departments and regions (DROM), compared to mainland France. Materials and Methods - The data were obtained from the National Health Data System (SNDS). Using ICD-10, CIP/UCD, and NABM codes, information was selected on patients newly diagnosed with HCC between 2015 and 2019, regardless of whether they had a viral hepatitis B or C infection. The prevalence of patients with a diagnosis of viral hepatitis B or C within the study population was calculated. Incidence rates, standardized to the 1960 global population age structure, for HCC and HCC with HBV or HCV were calculated. Results - Over the study period, 28,868 newly diagnosed patients hospitalized for HCC were selected. The mean age at HCC diagnosis was 69.1 years (standard deviation = 11.3) in mainland France and 64.5 years (standard deviation = 13.8) in the French overseas departments and regions (p < 0.001). The HCC incidence rates standardized to the global population were 4.15 per 100,000 person-years in mainland France and 1.95 per 100,000 person-years in the DROMs. The incidence rate of HCC with HBV was 0.50 per 100,000 person-years in mainland France and 0.60 per 100,000 person-years in the overseas departments and regions (DROM). For patients with HCC and HBV, the rate was 2.7 times higher in mainland France (0.92 per 100,000 person-years) than in the overseas departments and regions (0.34 per 100,000 person-years). Regardless of the region within the DROMs, the incidence rate of HBV-related HCC was higher than that of HCV-related HCC, except in Martinique. Conclusion - The incidence of HCC is half as high in the DROMs as in mainland France. The contribution of viral hepatitis to HCC diagnoses, with HBV predominating, is greater in the DROMs than in mainland France.